EPT Disclosure
May 30 2006 - 5:30AM
UK Regulatory
RNS Number:7337D
GoldmanSachs International
30 May 2006
FORM 38.5(a)
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITH RECOGNISED INTERMEDIARY STATUS
DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(a) of the Takeover Code)
1. KEY INFORMATION
Name of exempt principal trader Goldman Sachs International
Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
Class of relevant security to which the Ordinary Shares
dealings being disclosed relate (Note 1)
Date of dealing 26 May 2006
2. DEALINGS (Note 2)
(a) Purchases and sales
Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3)
2130 13.0149 GBP 13.0149 GBP
Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3)
20888 13.0404 GBP 13.0217 GBP
(b) Derivatives transactions (other than options)
Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)
e.g. CFD
CFD Long 10751 13.0378 GBP
CFD Long 9237 13.0378 GBP
CFD Short 900 13.0217 GBP
CFD Long 2130 13.0149 GBP
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money
purchasing, which the option relates American,
e.g. call varying etc. (Note 5) price European date paid/received per
option etc. unit (Note 3)
(ii) Exercising
Product name, e.g. call option Number of securities Exercise price per unit (Note 3)
3. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
Date of disclosure 30 May 2006
Contact name Peter Highton
Telephone number +44-207-774-1935
Name of offeree/offeror with which connected AstraZeneca
Nature of connection (Note 6) Advisor
Notes
The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
EMMSDIFSSSMSEEI
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Oct 2023 to Oct 2024